BBIO BridgeBio Pharma, Inc.
Price Chart
Executive Summary
BridgeBio Pharma announced it will present additional Phase 3 data for encaleret in ADH1 at the 2026 European Congress of Endocrinology, including an oral presentation of primary results. This is a routine data disclosure event with no new regulatory or financial catalysts — the data was already known from the Phase 3 trial.
Actionable Insight
This is a routine conference presentation announcement with no new data disclosed. Monitor the actual presentation on May 12 for any material efficacy or safety updates that could move the stock. No immediate trading action warranted.
Key Facts
- BridgeBio will present primary Phase 3 CALIBRATE trial results for encaleret in ADH1 at ECE 2026 on May 12
- Additional oral presentation on genetic testing of hypoparathyroidism patients
- One poster and one ePoster on ADH1 quality of life and epidemiology
- No new efficacy/safety data disclosed beyond the presentation schedule
- No regulatory submission, approval, or financial guidance provided
Financial Impact
No financial impact — this is a data presentation announcement with no new material information
Risk Factors
- No new data disclosed — market may have already priced in Phase 3 results
- ADH1 is a small patient population, limiting commercial upside even if positive
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287541 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
17d ago
|
Press Release
| $66.44 $63.88 | ▼ −3.85% | ▼ −5.06% | $66.80 (+0.54%) |
|
May 26, 2026
17d ago
|
Insider Cluster
| $66.44 $65.48 | ▲ +1.44% | ▲ +1.91% | $66.80 (−0.54%) |
|
May 21, 2026
22d ago
|
144
| $69.12 $65.36 | ▼ −5.44% | ▼ −7.10% | $66.80 (−3.36%) |
|
May 19, 2026
24d ago
|
Insider Cluster
| $68.22 $68.45 | ▲ +0.34% | ▼ −1.47% | $66.80 (−2.08%) |
|
May 12, 2026
4w ago
|
Press Release
| $65.95 $65.32 | ▼ −0.96% | ▼ −1.03% | $66.80 (+1.29%) |
|
May 11, 2026
4w ago
|
Press Release
| $64.68 $65.32 | ▲ +0.99% | ▲ +1.07% | $66.80 (+3.28%) |
|
May 8, 2026
5w ago
|
S-3ASR
| $67.39 $69.66 | ▲ +3.37% | ▲ +1.90% | $66.80 (−0.88%) |
|
May 7, 2026
5w ago
|
Press Release
| $67.39 $69.66 | ▲ +3.37% | ▲ +1.90% | $66.80 (−0.88%) |
|
May 6, 2026
5w ago
|
Press Release
| $68.09 $65.95 | ▼ −3.14% | ▼ −4.27% | $66.80 (−1.89%) |
|
May 5, 2026
5w ago
|
Press Release
| $68.78 $65.95 | ▼ −4.11% | ▼ −6.10% | $66.80 (−2.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access